

1 **High-throughput detection of neutralizing antibodies to**
2 **SARS-CoV-2 variants using flow cytometry**

3
4 **Running Head:** High-throughput broad SARS-CoV-2 variants
5 neutralizing assay

6
7 Xiaohan Zhang^{1,2*}, Yajie Wang^{3*}, Mansheng Li^{1*}, Haolong Li^{4*}, Xiaomei
8 Zhang¹, Xingming Xu¹, Di Hu⁵, Te Liang¹, Yunping Zhu¹, Yongzhe Li^{4#},
9 Bingwei Wang^{2#} and Xiaobo Yu^{1,6#}

10

11 **Affiliations**

12 ¹State Key Laboratory of Medical Proteomics, Beijing Proteome
13 Research Center, National Center for Protein Sciences-Beijing
14 (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206,
15 China.

16 ²School of Medicine, Nanjing University of Chinese Medicine, Nanjing
17 210023, China.

18 ³Department of Clinical Laboratory, Beijing Ditan Hospital, Capital
19 Medical University, Beijing 100015, China.

20 ⁴Department of Clinical Laboratory, Peking Union Medical College
21 Hospital, Chinese Academy of Medical Science & Peking Union
22 Medical College, Beijing 100730, China.

23 ⁵ProteomicsEra Medical Co., Ltd., Beijing, 102206, China

24 ⁶The First Affiliated Hospital of Wenzhou Medical University, Wenzhou,
25 China.

26 *These authors contributed equally to this work.

27 #Correspondence to xiaobo.yu@hotmail.com (X.Y.),
28 bingweiwang@njucm.edu.cn (B.W.) and yongzhelipumch@126.com (Y.
29 L).

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45 **Abstract**

46 Detecting neutralizing antibodies (NAbs) to SARS-CoV-2 variants is
47 crucial for controlling COVID-19 spread. We developed a
48 high-throughput assay for the broad systematic examination of NAbs to
49 eleven SARS-CoV-2 variants, which include D614G, Alpha, Beta,
50 Gamma, Delta, Kappa, and Omicron sub-lineages BA.1-BA.5. The
51 assay is cost-effective, reliable, 35-fold more sensitive than Luminex
52 technology, and can include new variants during SARS-CoV-2
53 evolution. Importantly, our results highly correlated with a commercial
54 IgG serological assay ($R = 0.89$) , the FDA-approved cPass sVNT
55 assay ($R = 0.93$), pseudivirus-based neutralizing assay ($R = 0.96$, $R =$
56 0.66 , $R = 0.65$) and live virus based neutralization assay ($R = 0.79$, $R =$
57 0.64) . Using this platform, we constructed a comprehensive overview
58 of the interactions between SARS-CoV-2 variants' Spike trimer proteins
59 and ACE2 receptors, and identified a polyclonal Ab with broad
60 neutralizing activity. Furthermore, when compared to the D614G
61 variant, we found that the serum NAbs elicited by the third dose
62 vaccine demonstrated decreased inhibition to multiple SARS-CoV-2
63 variants, including Gamma (0.94x), Alpha (0.91x), Delta (0.91x), Beta
64 (0.81x), Kappa (0.81x), BA.2 (0.44x), BA.1 (0.43x), BA.3 (0.41x), BA.5
65 (0.35x) and BA.4 (0.33x), in cohort of 56 vaccinated individuals.
66 Altogether, our proteomics platform proves to be an effective tool to

67 detect broad NAbS in the population and aid in the development of

68 future COVID-19 vaccines and vaccination strategies.

69 **Keywords**

70 SARS-CoV-2, flow cytometry, neutralization, antibody, COVID-19

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89 Introduction

90 The ongoing coronavirus 2019 (COVID-19) pandemic, caused by the
91 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
92 remains a public health concern worldwide. This is primarily attributed
93 to the continuous evolution of the virus and its persistent transmission
94 across global populations¹. For instance, over ten SARS-CoV-2
95 variants of concern (VOCs) have appeared, and these VOCs have the
96 potential to reduce the immune response². According to reports, 17.13%
97 (95%CI, 7.55–26.71%) of asymptomatic infected individuals may have
98 long-term health consequences³, which may include symptoms such
99 as fatigue, brain fog, dizziness, gastrointestinal symptoms, as well as
100 others⁴.

101 Neutralizing antibodies (NAbs) of SARS-CoV-2 are a subset of
102 antibodies that block viral entry by inhibiting the interaction between
103 the SARS-CoV-2's surface protein, Spike, and the host cell's receptor,
104 angiotensin-converting enzyme 2 (ACE2). Such NAbs can be
105 produced following COVID-19 vaccination or SARS-CoV-2 infection.
106 Identifying SAR-CoV-2 NAbs is critical for assessing vaccine efficacy,
107 evaluating individual and population immunity, monitoring variant
108 susceptibility, and information public health measures to control the
109 spread of COVID-19. However, traditional methods of NAb detection,
110 such those that use a live virus or a pseudovirus-based neutralization

111 assay, are slow, expensive, carry a potential risk of infection, and may
112 require specialized biosafety level 3 (BSL3) facilities⁵⁻⁸.

113 As an alternative approach, enzyme-linked immunosorbent assay
114 (ELISA) can perform the *in vitro* neutralizing testing using purified
115 Spike, ACE2, or Spike's receptor-binding domain (RBD) that interacts
116 directly with ACE2 during viral entry. Several commercial ELISA-based
117 surrogate virus neutralization tests (sVNT) have been developed,
118 including TECO sVNT (TECO Medical) and cPASS sVNT (GenScript),
119 which have been approved by the United States' (U.S.) Food and Drug
120 Administration (FDA) or received Conformance Européenne (CE)
121 marking for use in the European Union^{9,10}. Unfortunately,
122 ELISA-based methods only detect a single variant at a time, making
123 them a time-consuming option when multiple SARS-CoV-2 variants are
124 analyzed⁶.

125 To address this concern, Fenwick *et al.* developed a multiplexed
126 *in-vitro* quantitative neutralization assay using Luminex technology in
127 2021. The assay enables the detection of NAbs targeting various Spike
128 mutations, including D614G, D614G plus M153T, N439K, S477N,
129 S477R, E484K, S459Y, N501T, N501Y, K417N, 60-70, P681H, Y453F,
130 and their combinations. The results obtained from this assay correlated
131 with pseudovirus neutralization ($R^2=0.65$) and live virus infection ($R^2=$
132 0.825) assays⁷.

133 In a similar vein, Lynch et al. developed a multiplexed surrogate
134 virus neutralization test (plex-sVNT) for detecting NAbs to seven
135 SARS-CoV-2 variants, namely, wild type, Alpha, Beta, Gamma, Delta,
136 Kappa, and Epsilon. The results highly correlated (> 96%) with those
137 obtained from a plaque reduction neutralization test (PRNT)⁸.

138 However, it should be noted that these technologies have
139 limitations as they require access to specific Luminex and Bio-Rad
140 instruments, thereby restricting their use to specific laboratories.
141 Moreover, some recent Omicron variants have not been accessible for
142 analysis using these methods to date¹¹.

143 In this work, we developed a high-throughput broad neutralizing
144 antibody (bNAb) assay that enables the systematic detection of NAbs
145 to eleven SARS-CoV-2 VOCs that is reliable, cost-effective, sensitive,
146 and used with a standard flow cytometer¹². These variants include
147 D614G, Alpha, Beta, Gamma, Delta, Kappa, Omicron BA.1, Omicron
148 BA.2, Omicron BA.3, Omicron BA.4, and Omicron BA.5. We conducted
149 a comparative analysis of NAb detection using our SARS-CoV-2 bNAb
150 assay with commercial ELISA-based serology, U.S. FDA-approved
151 cPASS sVNT, pseudivirus-based neutralizing assays and live virus
152 based neutralization assay. Furthermore, we explored the applications
153 of the SARS-CoV-2 bNAb assay for screening therapeutic Abs,
154 assessing their neutralizing activity SARS-CoV-2. Finally, we analyzed

155 the broad responses of serological NAbs to SARS-CoV-2 variants in
156 individuals who received the third dose of either the inactivated vaccine
157 (Sinovac-CoronaVac) or the recombinant subunit vaccine (ZF2001) for
158 COVID-19.

159

160 **Results**

161 **Schematic illustration of SARS-CoV-2 bNAb assay**

162 In the SARS-COV-2 bNAb assay, illustrated schematically in Figure 1A,
163 the trimerized Spike proteins of six non-Omicron variants (D614G,
164 Alpha, Beta, Kappa, Gamma, Delta) and five Omicron variants (BA.1,
165 BA.2, BA.3, BA.4, BA.5) were expressed from human embryonic
166 kidney 293 (HEK293) cells, purified, and coupled to the
167 magnetic-fluorescent beads, as previously reported ^{7,13}. During the
168 NAbs detection process, all coupled beads were mixed together and
169 incubated with samples containing NAbs. The NAbs bound to the
170 Spike trimer proteins, preventing their interaction with the biotinylated
171 ACE2 receptors, which were coupled to streptavidin-phycoerythrin
172 (SA-PE). The inhibition rate (%) was calculated as follows: Inhibition
173 rate (%) = (1 - signal of NAb inhibition on Spike-ACE2 binding / signal
174 of Spike-ACE2 binding) × 100%.

175 The sensitive detection of Spike-ACE2 interactions is essential for
176 assessing the presence of NAbs in clinical samples. To address this

177 requirement, we coupled the Spike protein from six SARS-CoV-2
178 variants (D614G, Alpha, Beta, Kappa, Delta, Omicron BA.1) onto
179 magnetic-fluorescent beads from Luminex and Shenzhen Wellgrow
180 Technology Co., Ltd. (“Wellgrow”), and then incubated with different
181 concentrations of ACE2. Magnetic-fluorescent beads with the
182 SARS-CoV-2 nucleocapsid (N) protein, rather than the Spike protein,
183 was employed as the negative control. The binding signals were
184 measured using Luminex-200 and Wellgrow flow cytometry. Notably,
185 the fluorescent signal intensity and signal to noise ratio (SNR) were
186 much higher with the Wellgrow platform than the Luminex platform
187 when ACE2 concentrations ranged from 0.01 µg/mL to 100 µg/mL
188 (Figure 1B, Figure S1 and Table S6).

189 Furthermore, we calculated the sensitivity or the lowest detection
190 limit (LOD) of each method, in which the LOD was equal to the signal
191 of the buffer control plus ten standard deviations (Figure 1C). The data
192 showed that the average LOD of our assay using the Wellgrow
193 platform was 35.89 ± 57.8 [-21.91~93.69]-fold higher than the Luminex
194 platform for all variants (D614G, Alpha, Beta, Kappa, Delta, Omicron
195 BA.1).

196 At last, we compared the difference of NAb titers obtained by
197 detecting the inhibition of antibody #26 to Spike-ACE2 interaction. The
198 results showed that the IC50 obtained by two platforms are highly

199 consistence with the r correlation of 0.9988 (Figure S1D). Therefore,
200 we chose the Wellgrow platform as the proteomics platform for the
201 SARS-CoV-2 bNAb assay in this study.

202

203 **Mapping Spike-ACE2 interactions of SARS-CoV-2 variants**

204 Using our platform, we conducted a systematic investigation of the
205 interactions between ACE2 and Spike trimer proteins from eleven
206 SARS-CoV-2 variants. This was achieved by incubating a bead array
207 with different concentrations of ACE2 (Figure 2). The results
208 demonstrated that the fluorescent signals from the Spike trimer
209 proteins increased with increasing concentrations of ACE2, indicating
210 the formation of Spike-ACE2 complexes on the beads (Figure 2A).

211 Spike mutations were found to influence the interaction dynamics.
212 At the maximal concentration of 10 $\mu\text{g}/\text{mL}$ ACE2, Alpha and Delta
213 variants exhibited the highest signals, followed by Beta, BA.4, BA.5,
214 D614G, Gamma, BA.1, BA.2, and Kappa, with BA.3 showing the
215 lowest signal. In contrast, the N protein, used as a negative control,
216 consistently displayed the lowest signal regardless of ACE2
217 concentration.

218 To further assess the binding affinity, we calculated the
219 half-maximal effective concentration (EC50) using the standard curve
220 for each SARS-CoV-2 variant (Figure 2B). The results showed that

221 Omicron BA.1 has the highest binding affinity with an EC₅₀ of 0.2913
222 µg/mL, followed by Beta (0.2913 µg/mL), Delta (0.3415 µg/mL),
223 Omicron BA.4 (0.3592 µg/mL), Gamma (0.3833 µg/mL), Alpha (0.394
224 µg/mL), Kappa (0.3983 µg/mL), Omicron BA. 2 (0.4307µg/mL),
225 Omicron BA. 5(0.4593 µg/mL), D614G (0.5279 µg/mL), and Omicron
226 BA.3 (1.283 µg/mL). The results are in accordance with surface plasma
227 resonance data in which BA.1 has the strongest interaction with ACE2
228 with a dissociation constant (K_D) of 2.10 nM, followed by BA.2 (2.21 nM)
229 and D614G (5.20 nM)¹⁴. Similar results were obtained by Mahalingam
230 et al., who used ELISA to determine the EC₅₀ of ACE2 to Spike
231 Omicron (0.38 nM), Delta (0.48 nM), and wild type (2.28 nM)¹⁵.
232 Collectively, our data provide a comprehensive landscape of Spike
233 trimer-ACE2 interactions for SARS-CoV-2 VOCs, as classified by the
234 U.S. Centers for Disease Control and Prevention (CDC)
235 ([https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifica](https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html)
236 [tions.html](https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html)). It should be noted that the Epsilon variant was not included
237 in this work due to the unavailability of purified Spike trimer protein at
238 the time of executing experiments.

239 In addition, to demonstrate the specificity of our assay, we tested
240 the binding ability of ACE2 to the Spike proteins from MERS,
241 SARS-CoV and six SARS-CoV-2 variants. The results showed that the
242 binding signal of ACE2 to six SARS-CoV-2 variant Spike proteins was

243 much higher than that of SARS-CoV and MERS. The binding signal of
244 SARS-CoV was 3.38-5.74 times lower than that of SARS-CoV-2
245 variants, due to the homology of Spike sequence. There was no
246 binding signal observed between ACE2 and MERS, similar to the
247 negative control, N protein (Figure S2). All these results are accord to
248 the reported results¹⁶, and demonstrate our assay is specific.

249

250 **Comparison of SARS-CoV-2 bNAb assay to ELISA , cPass sVNT,**
251 **pseudovirus-based neutralization and live virus based**
252 **neutralization assays.**

253 To assess the reliability of the SARS-CoV-2 bNAb assay, we compared
254 the SARS-CoV-2 bNAb assay to an ELISA that was used to detect
255 anti-Spike IgG antibodies¹⁷. The results showed a high correlation
256 between the levels of D614G NAb detected using our SARS-CoV-2
257 bNAb assay and the anti-Spike IgG antibodies obtained by the ELISA
258 [R = 0.89, p-value (p) < 2.2 e-16] in a cohort of 75 individuals (Figure
259 3A).

260 Next, we compared the NAb results obtained from the
261 SARS-CoV-2 bNAb assay to those obtained from the FDA-approved
262 cPass sVNT test^{6,9}. The data obtained using the SARS-CoV-2 bNAb
263 assay and cPass sVNT test demonstrated a higher correlation to each
264 other (R = 0.93, p < 2.2 e-16) compared to the assay using Luminex

265 technology ($R = 0.85$)¹⁸. The positive percent agreement (PPA) was
266 92.7% (80.1%-98.5%) and the negative percent agreement (NPA) was
267 94.1% (80.3%-99.3%) (Figure 3B). The findings suggest that some of
268 the anti-Spike IgG antibodies detected by the ELISA may lack
269 neutralizing activity and therefore were not detected by SARS-CoV-2
270 bNAb assay¹⁹. Overall, these results demonstrate the reliability of the
271 SARS-CoV-2 bNAb assay as an *in vitro* platform for detecting serum
272 NAbs.

273 Additionally, we compared the inhibition rate (%) of NAbs obtained
274 by SARS-CoV-2 bNAb assay to the NAb titers obtained by
275 pseudovirus-based neutralization assay or live virus based
276 neutralization assay. For 10 serum samples from mice administered
277 with WT mRNA vaccines, a high correlation was found between D614G
278 NAbs inhibition rate (%) detected using SARS-CoV-2 bNAb assay and
279 WT NAb titers by pseudovirus-based neutralization assay ($R = 0.96$, p
280 < 0.0001) and live virus based neutralization assay ($R = 0.79$, $p <$
281 0.0001) (Figures 3C, 3E). Similarly, for 10 serum samples from mice
282 administered with BA.1 mRNA vaccines, notable correlations were
283 observed between the levels of BA.1 NAbs detected using
284 SARS-CoV-2 bNAb assay and pseudovirus-based neutralization ($R =$
285 0.66 , $p = 0.0017$) and live virus based neutralization assays ($R = 0.64$,
286 $p = 0.0022$) (Figures 3D, 3F). Then, we compared the inhibition rate (%)

287 of NAbS obtained by SARS-CoV-2 bNAb assay and the NAb titers
288 obtained by pseudovirus-based neutralization assay in the serum of
289 135 individuals with second dose vaccination. We detected serum
290 NAbS against the D614G variant using both assays. The results
291 showed a correlation coefficient (r) of 0.65, demonstrating the
292 consistency between the results obtained through inhibition and those
293 obtained with NAb titers (Figure S4 and Table S7).

294

295 **Identification of broadly neutralizing monoclonal/polyclonal Abs**
296 **against SARS-CoV-2 variants**

297 To demonstrate the application of SARS-CoV-2 bNAb assay in
298 identifying monoclonal/polyclonal NAbS for potential treatment
299 purposes, we tested six anti-Spike antibodies that are available in the
300 laboratory²⁰ (Figure 4A). The results revealed that three antibodies
301 (#26, #20, #21) have neutralizing activity. Antibodies #20 and #21
302 inhibited ACE2 binding to D614G, Alpha, Beta, Kappa and Delta
303 variants, but were not effective in inhibiting the ACE2 binding to the
304 Omicron BA.1 variant. Antibody #26 exhibited the ability to inhibit
305 Spike-ACE2 interactions for D614G, Alpha, Beta, Kappa, Delta and
306 Omicron BA.1 variants.

307 Subsequently, the half-maximal inhibitory concentration (IC₅₀)
308 values were calculated and represented in a heatmap (Figure 4B). The

309 results showed that antibody #26 possessed broad neutralizing activity
310 to all tested SARS-CoV-2 variants (Kappa, D614G, Alpha, Delta, Beta,
311 Omicron BA.1). The IC₅₀ to D614G (0.47 µg/mL) was confirmed with
312 ELISA (0.35 µg/mL) and pseudovirus neutralizing assay (0.21 µg/mL)
313 in our previous work²⁰. While the IC₅₀ of antibody #26 to the Omicron
314 variant was ten-fold lower than non-Omicron variants. These findings
315 underscore the ability of our assay to rapidly screen for
316 monoclonal/polyclonal NABs with potential therapeutic applications.

317

318 **Evaluation of serum NABs in individuals receiving the third dose** 319 **vaccination**

320 We tested the serum NABs from 56 individuals who received two doses
321 of the inactivated vaccine (Sinovac-CoronaVac) and boosted with a
322 third dose with either an inactivated vaccine or recombinant subunit
323 vaccine (ZF2001) (Table 1)²¹. The inhibition rate (%) was calculated by
324 deducting the background noise using 147 serum samples collected
325 prior to the COVID-19 pandemic²². The results showed that the third
326 dose vaccination elicited a strong protective immune response against
327 the non-Omicron variants with the highest inhibition rate (%) of D614G,
328 followed by Gamma, Alpha, Delta, and Kappa variants. Unfortunately,
329 the inhibition rate (%) was much lower in Omicron BA.2 (0.44x), BA.1
330 (0.43x), BA.3 (0.41x), BA.5 (0.35x), and BA.4 (0.33x) variants,

331 indicating the resistance of these variants to the Sinovac-CoronaVac
332 vaccine and the ZF2001 vaccine (Figure 5A).

333 Next, we compared the inhibition (%) of serum NAb's in individuals
334 who received either a third dose of inactivated vaccine or recombinant
335 vaccine; no significant difference was observed (Figure 5B). These
336 findings highlight the immunological resistance of different
337 SARS-CoV-2 variants to the Sinovac-CoronaVac and ZF2001 vaccines,
338 and suggest the need for developing a new vaccine that provides
339 broad protection against SARS-CoV-2 variants.

340 Furthermore in order to demonstrate the specificity of our
341 SARS-CoV-2 bNAb assay, we detected the serum from the individuals
342 before vaccination (n = 147) and after three-dose vaccination (n = 56).
343 The results showed that the serum NAb levels were significantly higher
344 in the vaccination group than un-vaccination group ($p < 0.0001$) (Figure
345 S3), indicating our SARS-CoV-2 bNAb assay is highly specific for the
346 detection of serum NAb's.

347

348 **Discussion**

349 Even though the World Health Organization has announced that
350 COVID-19 is no longer a public health emergency of international
351 concern, the genome sequence of SARS-CoV-2 is continually evolving
352 and the new variants (i.e. EG.5) may have the potential to escape the

353 immunity and threat the people's health, especially among
354 immunocompromised individuals^{23,24}. Therefore, there is still a need for
355 effective COVID-19 vaccines to prevent and control viral transmission.
356 The development and deployment of vaccines for COVID-19, as well
357 as the evaluation of population immunity, remain important for public
358 health²⁵.

359 In this work, we developed a high-throughput SARS-CoV-2 bNAb
360 assay to detect a wide range of NAb to non-Omicron and Omicron
361 variants. Compared to the assay using Luminex technology^{7,8}, our
362 SARS-CoV-2 bNAb assay is 35-fold more sensitive, 2.5-fold less costly,
363 and can be accessible to any laboratory that has a standard flow
364 cytometer with the 532 nm and 635 nm lasers. Moreover, the
365 simultaneous detection of NAb to multiple SARS-CoV-2 variants can
366 be achieved within a single experiment, and the assay can be
367 periodically updated to include new variants. The reliability of NAb
368 detection using our SARS-CoV-2 bNAb assay is demonstrated through
369 comparisons with ELISA-based IgG serology, the cPass sVNT assay,
370 pseudovirus-based neutralization assay and live virus based
371 neutralization assay (Figure 3).

372 Using this platform, we constructed a comprehensive landscape of
373 Spike trimer and ACE2 interactions for eleven SARS-CoV-2 variants
374 (Figure 2). The results provide evidence that Omicron BA.1 showed the

375 strongest binding affinity to the ACE2 receptor^{26,27}. Notably, the
376 transmission rate of SARS-CoV-2 and its variants is dependent on
377 numerous factors, including immune resistance, toxicity, etc²⁸.

378 Furthermore, our investigation of serum NAbS in vaccinated
379 individuals showed that the third dose of the inactivated vaccine or
380 recombinant RBD vaccine resulted in a strong inhibition of Spike-ACE2
381 interactions to the non-Omicron variants (D614G, Alpha, Beta, Gamma,
382 Kappa). However, the protection was significantly decreased for
383 Omicron variants (BA.2, BA.1, BA.3, BA.5, BA.4) (Figure 5). These
384 results demonstrate the significance of our proteomics platform in
385 evaluating the broad protective activity of COVID-19 vaccines, which
386 can guide the development of COVID-19 vaccines.

387 It is important to acknowledge some limitations of our study. First,
388 the *in vitro* detection of NAbS may not represent viral neutralization *in*
389 *vivo*, although previously reported evidence has shown a good
390 correlation between NAbS detected *in vitro* and *vivo*⁵⁻⁸. Second, the
391 relationship between the inhibition levels obtained with the
392 SARS-CoV-2 bNAb assay and the SARS-CoV-2 infection remains
393 unclear. Third, the number of clinical samples employed in this study
394 was limited, and the assay should be executed in a larger cohort to
395 determine the NAb levels induced by different vaccines and infection
396 with SARS-CoV-2 variants. Finally, the SARS-CoV-2 wild-type was not

397 employed due to the unavailability of this protein during executing
398 experiments. Instead, we employed the D614G variant, which shares
399 high homology with the wild type. Previous studies have demonstrated
400 comparable neutralization potency between the D614G variant and the
401 wild type²⁹. Additionally, the D614G substitution does not significantly
402 alter SARS-CoV-2 morphology and binding to the ACE2 receptor³⁰.

403

404 **Conclusion**

405 We have successfully developed and validated a high-throughput
406 proteomics platform, enabling the comprehensive evaluation of NAbs
407 against a wide range of SARS-CoV-2 variants. This platform offers an
408 efficient, sensitive, and cost-effective approach for detecting broad
409 NAbs within the population, providing an opportunity to guide the
410 design and evaluation of vaccines with enhanced protective efficacy
411 against evolving SARS-CoV-2 strains. Overall, our work contributes to
412 the ongoing efforts in combating the COVID-19 pandemic and
413 advancing our understanding of immune responses to SARS-CoV-2.

414

415 **References**

- 416 1. The L. The COVID-19 pandemic in 2023: far from over. *Lancet*. 2023;401(10371):79.
- 417 2. Khoury DS, Docken SS, Subbarao K, et al. Predicting the efficacy of variant-modified
418 COVID-19 vaccine boosters. *Nat Med*. 2023;29(3):574-578.
- 419 3. Ma Y, Deng J, Liu Q, et al. Long-Term Consequences of Asymptomatic SARS-CoV-2
420 Infection: A Systematic Review and Meta-Analysis. *Int J Environ Res Public Health*.
421 2023;20(2).

- 422 4. Thaweethai T, Jolley SE, Karlson EW, et al. Development of a Definition of Postacute
423 Sequelae of SARS-CoV-2 Infection. *JAMA*. 2023.
- 424 5. Nie J, Li Q, Wu J, et al. Quantification of SARS-CoV-2 neutralizing antibody by a
425 pseudotyped virus-based assay. *Nat Protoc*. 2020;15(11):3699-3715.
- 426 6. Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test
427 based on antibody-mediated blockage of ACE2-spike protein-protein interaction.
428 *Nat Biotechnol*. 2020;38(9):1073-1078.
- 429 7. Fenwick C, Turelli P, Pellaton C, et al. A high-throughput cell- and virus-free assay
430 shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent
431 plasma. *Sci Transl Med*. 2021;13(605).
- 432 8. Lynch KL, Zhou S, Kaul R, et al. Evaluation of Neutralizing Antibodies against
433 SARS-CoV-2 Variants after Infection and Vaccination Using a Multiplexed Surrogate
434 Virus Neutralization Test. *Clin Chem*. 2022;68(5):702-712.
- 435 9. Perkmann T, Mucher P, Osze D, et al. Comparison of five Anti-SARS-CoV-2 antibody
436 assays across three doses of BNT162b2 reveals insufficient standardization of
437 SARS-CoV-2 serology. *J Clin Virol*. 2023;158:105345.
- 438 10. Bal A, Pozzetto B, Traub MA, et al. Evaluation of High-Throughput SARS-CoV-2
439 Serological Assays in a Longitudinal Cohort of Patients with Mild COVID-19: Clinical
440 Sensitivity, Specificity, and Association with Virus Neutralization Test. *Clin Chem*.
441 2021;67(5):742-752.
- 442 11. Grant R, Sacks J, Abraham P, et al. When to update COVID-19 vaccine composition.
443 *Nature Medicine* 2023(29):776–780.
- 444 12. Chao Z, Han Y, Jiao Z, et al. Prism Design for Spectral Flow Cytometry.
445 *Micromachines (Basel)*. 2023;14(2).
- 446 13. Yu X, Hartmann M, Wang Q, et al. microFBI: a microfluidic bead-based
447 immunoassay for multiplexed detection of proteins from a microL sample volume.
448 *PLoS One*. 2010;5(10).
- 449 14. Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron
450 subvariants BA.2.12.1, BA.4 and BA.5. *Nature*. 2022;608(7923):603-608.
- 451 15. Mahalingam G, Arjunan P, Periyasami Y, et al. Correlating the differences in the
452 receptor binding domain of SARS-CoV-2 spike variants on their interactions with
453 human ACE2 receptor. *Sci Rep*. 2023;13(1):8743.
- 454 16. Gorbalenya AE, Baker SC, Baric RS, et al. The species Severe acute respiratory
455 syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2.
456 *Nature Microbiology*. 2020;5(4):536-544.
- 457 17. Zhan H, Gao H, Liu Y, et al. Booster shot of inactivated SARS-CoV-2 vaccine induces
458 potent immune responses in people living with HIV. *J Med Virol*.
459 2023;95(1):e28428.
- 460 18. Marien J, Michiels J, Heyndrickx L, et al. Evaluation of a surrogate virus
461 neutralization test for high-throughput serosurveillance of SARS-CoV-2. *J Virol*
462 *Methods*. 2021;297:114228.
- 463 19. Chen Y, Zhao X, Zhou H, et al. Broadly neutralizing antibodies to SARS-CoV-2 and
464 other human coronaviruses. *Nat Rev Immunol*. 2023;23(3):189-199.
- 465 20. Liang T, Cheng M, Teng F, et al. Proteome-wide epitope mapping identifies a

- 466 resource of antibodies for SARS-CoV-2 detection and neutralization. *Signal*
467 *Transduct Target Ther.* 2021;6(1):166.
- 468 21. Zhao X, Zhang R, Qiao S, et al. Omicron SARS-CoV-2 Neutralization from Inactivated
469 and ZF2001 Vaccines. *N Engl J Med.* 2022;387(3):277-280.
- 470 22. Zhang J, Teng F, Zhang X, et al. Down-regulation of SARS-CoV-2 neutralizing
471 antibodies in vaccinated smokers. *MedComm (2020).* 2022;3(3):e166.
- 472 23. Faraone JN, Qu P, Goodarzi N, et al. Immune evasion and membrane fusion of
473 SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3. *Emerging Microbes & Infections.*
474 2023;12(2).
- 475 24. Antinori A, Bausch-Jurken M. The Burden of COVID-19 in the Immunocompromised
476 Patient: Implications for Vaccination and Needs for the Future. *The Journal of*
477 *Infectious Diseases.* 2023;228(Supplement_1):S4-S12.
- 478 25. Lotfi H, Mazar MG, Ei NMH, et al. Vaccination is the most effective and best way to
479 avoid the disease of COVID-19. *Immunity, Inflammation and Disease.* 2023;11(8).
- 480 26. Yin W, Xu Y, Xu P, et al. Structures of the Omicron spike trimer with ACE2 and an
481 anti-Omicron antibody. *Science.* 2022;375(6584):1048-1053.
- 482 27. Ma W, Fu H, Jian F, et al. Immune evasion and ACE2 binding affinity contribute to
483 SARS-CoV-2 evolution. *Nat Ecol Evol.* 2023.
- 484 28. Markov PV, Katzourakis A, Stilianakis NI. Antigenic evolution will lead to new
485 SARS-CoV-2 variants with unpredictable severity. *Nat Rev Microbiol.*
486 2022;20(5):251-252.
- 487 29. Yurkovetskiy L, Wang X, Pascal KE, et al. Structural and Functional Analysis of the
488 D614G SARS-CoV-2 Spike Protein Variant. *Cell.* 2020;183(3):739-751 e738.
- 489 30. Hou YJ, Chiba S, Halfmann P, et al. SARS-CoV-2 D614G variant exhibits efficient
490 replication ex vivo and transmission in vivo. *Science.* 2020;370(6523):1464-1468.
- 491 31. Zhang X, Zheng M, Wang H, et al. Inhibitor screening using microarray identifies the
492 high capacity of neutralizing antibodies to Spike variants in SARS-CoV-2 infection
493 and vaccination. *Theranostics.* 2022;12(6):2519-2534.
- 494 32. Yang L, Yu Y, Ma C, et al. Development of RBC Membrane Antigen Arrays for
495 Validating Blood Grouping Reagents. *J Proteome Res.* 2018;17(9):3237-3245.
- 496 33. Salazar-García M, Acosta-Contreras S, Rodríguez-Martínez G, et al. Pseudotyped
497 Vesicular Stomatitis Virus-Severe Acute Respiratory Syndrome-Coronavirus-2 Spike
498 for the Study of Variants, Vaccines, and Therapeutics Against Coronavirus Disease
499 2019. *Frontiers in Microbiology.* 2022;12.
- 500 34. Nie J, Li Q, Wu J, et al. Establishment and validation of a pseudovirus neutralization
501 assay for SARS-CoV-2. *Emerging Microbes & Infections.* 2020;9(1):680-686.
- 502 35. Chen G-L, Li X-F, Dai X-H, et al. Safety and immunogenicity of the SARS-CoV-2
503 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind,
504 placebo-controlled, phase 1 trial. *The Lancet Microbe.* 2022;3(3):e193-e202.
- 505 36. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to
506 analyze and compare ROC curves. *BMC Bioinformatics.* 2011;12:77.

507

508 **Contributions**

509 X.Z. and D.H. executed the experiments; M.L., X. Z., X.Z., X.X., T. L.,
510 and Y. Z. performed the data analysis; H.L. and Y.W. provided the
511 clinical samples. X.Y., Y. L., B.W. and X.Z. wrote and revised the paper.

512

513 **Acknowledgment**

514 This work was supported by the Beijing Municipal Natural Science
515 Foundation (M23010 and L234034), National Key R&D Program of
516 China(2022YFE0210400, 2021YFA1301604, 2020YFE0202200),
517 State Key Laboratory of Proteomics (SKLP-O202007), Academic
518 leader of high-level public health technical personnel construction
519 project of Beijing Municipal Health Commission (2022-2-014),
520 Guangdong Province Science and Technology Planning Project
521 (2020B1111100006), Innovation Team and Talents Cultivation Program
522 of National Administration of Traditional Chinese Medicine. (No:
523 ZYYCXTD-C-202204). We would like to thank the bioinformatics
524 platform of the National Center for Protein Sciences (Beijing) for their
525 support in the data analysis of this project. We also thank Dr. Brianne
526 Petritis for her critical review and editing of this manuscript.

527

528 **Declaration of Interest Statement**

529 The authors have declared no conflict of interest.

530

531 **Supplementary materials**

532 This article contains Supplementary Figure 1-4 and Supplementary

533 Table1-7.

534

535 **Tables**

536 Table 1. Clinical serum samples employed in this study

3rd dose vaccination cohort		
(n=56)		
Gender		
	Male	16(28.6%)
	Female	40(71.4%)
Age (years)		
	Range	21-70
	≤50	50(89.3%)
	>50	6(10.7%)
Vaccination type		
	Recombinant RBD-subunit vaccine (ZF2001)	38(83.9%)
	Inactivated vaccine (Sinovac-Coron aVac)	18(16.1%)
Days of serum collection after 3rd dose vaccination		28

537

538 **Figure legends**

539 **Figure 1. Schematic illustration of the high throughput**

540 **SARS-CoV-2 bNAb assay.** (A) Workflow of the SARS-CoV-2 bNAb

541 assay. The Spike-ACE2 interaction is a direct binding reaction between

542 Spike trimer proteins and biotinylated ACE2. Upon the addition of the

543 NAbs, the beads coupled with SARS-CoV-2 variants Spike trimer
544 proteins are incubated with NAbs. The NAbs with neutralizing activity
545 will block the Spike interaction with biotinylated ACE2 and SA-PE. The
546 signal intensities of the Spike trimer-ACE2 interaction are inversely
547 proportional to the level of NAbs. During the NAbs detection process,
548 all coupled beads were mixed together and incubated with samples
549 containing NAbs. The NAbs bound to the Spike trimer proteins,
550 preventing their interaction with the biotinylated ACE2 receptors, which
551 were coupled to streptavidin-phycoerythrin (SA-PE). (B) Dose
552 relationship curve of Spike-ACE2 interactions using Wellgrow and
553 Luminex platforms. MFI = mean fluorescence intensity. (C) A
554 comparison of the sensitivity to detect Spike-ACE2 interactions with the
555 Wellgrow and Luminex platforms.

556

557 **Figure 2. Spike trimer-ACE2 interactions across different**
558 **SARS-CoV-2 variants and ACE2 concentrations.** (A) Dose
559 relationship curve of the interactions between ACE2 and six
560 SARS-CoV-2 non-Omicron variants and five Omicron variants The
561 x-axis represents the concentrations of the host ACE2 receptor. The
562 y-axis represents the median of fluorescent signal intensity (MFI) of the
563 SARS-CoV-2 Spike trimer-ACE2 interaction. N = nucleocapsid protein,
564 which was used as a negative control. (B) Distribution of the NAb

565 resistance to SARS-CoV-2 variants. The x-axis represents the
566 SARS-CoV-2 variants. The y-axis represents the EC50 calculated from
567 SARS-CoV-2 variant Spike-ACE2 interactions. The corresponding
568 values on the Y-axis are Omicron BA.1 (0.2913 $\mu\text{g/mL}$), Beta (0.2913
569 $\mu\text{g/mL}$), Delta (0.3415 $\mu\text{g/mL}$), Omicron BA.4 (0.3592 $\mu\text{g/mL}$), Gamma
570 (0.3833 $\mu\text{g/mL}$), Alpha (0.394 $\mu\text{g/mL}$), Kappa (0.3983 $\mu\text{g/mL}$), Omicron
571 BA. 2 (0.4307 $\mu\text{g/mL}$), Omicron BA. 5(0.4593 $\mu\text{g/mL}$), D614G (0.5279
572 $\mu\text{g/mL}$), and Omicron BA.3 (1.283 $\mu\text{g/mL}$), respectively.

573

574 **Figure 3. Comparison of SARS-CoV-2 bNAb assay to ELISA ,**
575 **cPass sVNT, pseudovirus-based neutralization and live virus**
576 **based neutralization assays.** (A) Correlation analysis of serological
577 IgG detection between the SARS-CoV-2 bNAb assay and an
578 ELISA-based IgG serology. (B) Correlation analysis of NAb detection
579 using the SARS-CoV-2 bNAb assay and the FDA-approved cPass
580 sVNT test. The concordance of NAb detection using the ELISA and
581 sVNT assays was calculated as the positive and negative percent
582 agreement (PPA and NPA, respectively). The blue and red dots
583 represent positive (neutralizing activity) and negative (non-neutralizing)
584 cases as determined by the comparative analysis, respectively. (C)
585 Correlation analysis of D614G NAb's inhibition rate (%) from the
586 SARS-CoV-2 bNAb assay with WT NAb titers from pseudovirus-based

587 neutralization assays. (D) Correlation analysis of BA.1 NAb inhibition
588 rate (%) from the SARS-CoV-2 bNAb assay with BA.1 NAb titers from
589 pseudovirus-based neutralization assays. (E) Correlation analysis of
590 D614G NAb inhibition rate (%) from the SARS-CoV-2 bNAb assay
591 with WT NAb titers from live virus based neutralization assays. (F)
592 Correlation analysis of BA.1 NAb inhibition rate (%) from the
593 SARS-CoV-2 bNAb assay with BA.1 NAb titers from live virus based
594 neutralization assays.

595

596 **Figure 4. Identification of monoclonal/polyclonal Abs with broad**
597 **neutralizing capability.** (A) Dose relationship curve demonstrating the
598 ability of the NAb to inhibit SARS-CoV-2 variant Spike trimer-ACE2
599 interactions. The x-axis represents the concentrations of the NAb. The
600 y-axis represents the percent activity (%) of the NAb. N = nucleocapsid
601 protein, which was used as a negative control. (B) Heatmap showing
602 the IC50 of NAb against different SARS-CoV-2 variants. The detail of
603 monoclonal/polyclonal Abs are provided in Table S5.

604

605 **Figure 5. Detection of serum NAb in vaccinated individuals.** (A)
606 Boxplot showing the distribution of inhibition rate (%) of serum NAb
607 against SARS-CoV-2 variants in 56 vaccinated individuals. (B)
608 Comparison of NAb produced between groups receiving the

609 inactivated vaccine (Sinovac-CoronaVac) or recombinant subunit
610 vaccine (ZF2001). The significance was performed using the Student's
611 *t*-test (p-value < 0.01). **, ***, and **** represent a p-value less than
612 0.01, 0.001, and 0.0001, respectively.

613

614 **Materials and methods**

615 **Collection of clinical samples**

616 Clinical serum samples were collected from Beijing Ditan Hospital 28
617 days after the third dose of the COVID-19 vaccine (Table 1). Whole
618 blood was collected in a vacutainer tube, and the serum was obtained
619 via centrifugation at 4,000 × g at room temperature for 10 minutes. The
620 serum was then transferred to a clean tube and stored at -80 °C until
621 use. This study was approved by the Ethics Committee of Beijing Ditan
622 Hospital (No.2021-010-01), and an exemption of informed consent was
623 obtained before sera collection³¹.

624

625 **Preparation of SARS-CoV-2 bNAbs reagents**

626 The SARS-CoV-2 bNAbs assay was developed in ProteomicsEra
627 Medical Co., Ltd (Beijing, China). Briefly, 3 µg SARS-CoV-2 Spike
628 trimer proteins (Sino Biological., Novoprotein and ACROBiosystems;
629 China) (Table S1) were coupled to 1×10⁶ magnetic-fluorescent beads
630 (Wellgrow Technology Co., Ltd.) as previously described³². First, 12

631 differently encoded magnetic-fluorescent beads, numbered 102-108
632 and 201-205 (Table S2), were chosen. Then 125 μL containing
633 1×10^6 beads were washed with 100 μL ddH₂O and activated with 80
634 μL of "activation buffer" (50 mM 2-(N-morpholino) ethanesulfonic acid
635 (MES) pH 5.0) (Sigma-Aldrich, St. Louis, MO). Then the activated
636 beads were mixed with 10 μL of 50 mg/mL sulfo-N-hydroxysuccinimide
637 (NHS) (Thermo Scientific, USA) and 10 μL of 50 mg/mL
638 1-Ethyl-3-[3-dimethylaminopropyl]-carbodiimide hydrochloride (EDC)
639 (Solarbio, Beijing, China). After incubation for 20 min at room
640 temperature with gentle mixing, the beads were washed twice with 250
641 μL "coupling buffer" (50 mM MES pH 5.0) and resuspended in 200 μL
642 coupling buffer. Then 3 μg of Spike trimer proteins were added to the
643 bead solution and incubated for 2 h at room temperature. After washing,
644 the beads underwent blocking with "blocking buffer" (PBST-B, PBS pH
645 7.4, 0.05% Tween-20, 1% BSA), and the coupled beads were
646 subsequently stored at 2-8 °C in "storage buffer" (PBST-BN, PBS pH
647 7.4, 0.05% Tween-20, 0.1% BSA, 0.05% NaN₃).

648

649 **Detection of Spike-ACE2 interactions using SARS-CoV-2 bNAbs** 650 **assay**

651 First, a 50 μL mixed solution containing 12 different SARS-CoV-2 Spike
652 trimer protein-coupled beads (2500 beads per type) (Table S3) was

653 added to each well of a 96-well plate, followed by 50 μ L of different
654 concentrations (0, 0.014, 0.041, 0.123, 0.370, 1.111, 3.333, 10 μ g/mL)
655 of biotinylated ACE2 (Sino Biological). After incubation for 1 h at room
656 temperature on a shaker, the beads were magnetically separated using
657 a magnetic separator (Wellgrow Technology Co., Ltd.) and washed
658 three times with 100 μ L PBST-B (PBS pH7.4 , 0.05% Tween-20, 0.1%
659 BSA). After washing, the Spike-ACE2 interaction was detected using
660 50 μ L SA-PE (Thermo Scientific, USA) (2 μ g/mL) for 30 minutes at
661 room temperature. Finally, after washing with PBST-B twice, the beads
662 were resuspended in a 200 μ L PBST-B solution. The fluorescent signal
663 was then detected at 200 beads/region using the EasyCell flow
664 cytometry (Wellgrow Technology Co., Ltd.) with excitation wavelengths
665 of 532 nm and 635 nm.

666

667 **Detection of monoclonal/polyclonal NAbS using the SARS-CoV-2**
668 **bNAb assay**

669 To detect monoclonal/polyclonal NAbS, a 50 μ L mixed solution
670 containing 7 different SARS-CoV-2 Spike trimer protein-coupled beads
671 (2500 beads per type) (Table S4) was added to each well of a 96-well
672 plate. Following that, 50 μ L of each antibody solution at different
673 concentrations (0, 0.014, 0.041, 0.123, 0.370, 1.111, 3.333, 10 μ g/mL)
674 for anti-Spike antibodies (#26, #20, #21, #22, #23, #73) (Table S5) was

675 added to individual wells of a 96-well plate. After incubation for 2 h at
676 room temperature on a shaker, the beads were washed with PBST-B
677 three times, then the beads were incubated with 50 μ L biotinylated
678 ACE2 (0.5 μ g/mL) for 1 hour at room temperature. After washing, the
679 binding of ACE2 to Spike trimer proteins were detected using 50 μ L
680 SA-PE (2 μ g/mL) for 30 minutes at room temperature. Finally, after
681 washing with PBST-B twice, the beads were resuspended in a 200 μ L
682 PBST-B solution. The fluorescent signal was then detected at 200
683 beads/region using the EasyCell flow cytometry (Wellgrow Technology
684 Co., Ltd.) with excitation wavelengths of 532 nm and 635 nm.

685

686 **Detection of Serum NAbS using SARS-CoV-2 bNAb assay.**

687 First, a 50 μ L mixed solution containing 12 different SARS-CoV-2 Spike
688 trimer protein-coupled beads (2500 beads per type) (Table S2) was
689 added to each well of a 96-well plate, followed by 50 μ L of the serum
690 samples which were diluted to 1:20 with PBST-B. After incubation for 2
691 h at room temperature on a shaker, the beads were washed with
692 PBST-B three times. Then the beads were incubated with 50 μ L
693 biotinylated ACE2 (0.5 μ g/mL) for 1 hour at room temperature. After
694 washing, the binding of ACE2 to Spike trimer proteins were detected
695 using 50 μ L SA-PE (2 μ g/mL) and incubated the mixture for 30 minutes
696 at room temperature. Finally, after washing with PBST-B twice, the

697 beads were resuspended in a 200 μ L PBST-B solution. The fluorescent
698 signal was then detected at 200 beads/region using the EasyCell flow
699 cytometry (Wellgrow Technology Co., Ltd.) with excitation wavelengths
700 of 532 nm and 635 nm.

701

702 **Detection of Serum NAbs using the anti-Spike RBD IgG antibodies**
703 **obtained by the ELISA.**

704 The assay was conducted as described previously¹⁷. A capture
705 sandwich ELISA detection kit (PROPRIUM, Hangzhou, China) was
706 used to detect SARS-CoV-2 antibodies against the Spike protein RBD.
707 The SARS-CoV-2 Spike RBD protein was pre-coated onto the solid
708 phase, allowing it to form an antigen-antibody complex with IgG
709 anti-RBD antibodies from 100 μ L of diluted serum samples (1:30
710 dilution ratio) or standards. After washing, HRP-conjugated anti-human
711 IgG was added to form an antigen-antibody-HRP complex. The
712 substrate solution TMB was then introduced, and the resulting color
713 intensity was proportional to the level of SARS-CoV-2-neutralizing
714 antibodies. The optical density (OD) at 450 nm was measured, and a
715 threshold of 10 BAU/ml was used to determine sero-positive and
716 negative samples for anti-Spike RBD IgG.

717

718 **Detection of Serum NAbs using cPassTM sVNT Kit.**

719 The assay was conducted as described previously¹⁷. Using competitive
720 ELISA, the SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT)
721 assay (Genscript, Nanjing, China) identified neutralizing antibodies
722 present in the bloodstream that obstruct the interaction between the
723 viral Spike glycoprotein receptor-binding domain (RBD) and human
724 ACE2. Following the manufacturer's instructions, diluted serum
725 samples (1:10 dilution ratio) and controls were pre-incubated at 37°C for
726 15 minutes to allow binding of neutralizing antibodies (NAb) and
727 HRP-RBD (antigen derived from SARS-CoV-2 variant D614G), using a
728 1:1 volume ratio. Subsequently, the mixture was transferred to a
729 capture plate, pre-coated with hACE2 protein, where NAb-unbound
730 HRP-RBD was captured on the plate, while NAb-bound HRP-RBD
731 remained in the supernatant and was washed away. Next, 100 µL of
732 TMB and 50 µL of stop solution were added, and the plate was read at
733 450 nm. The sample's absorbance was inversely correlated with the
734 titers of anti-SARS-CoV-2-neutralizing antibodies. To ensure result
735 validity, the OD450 values of positive controls (> 1.0) and negative
736 controls (< 0.3) had to fall within specific ranges. An inhibition rate of ≥
737 30% was considered positive for SARS-CoV-2-neutralizing antibody
738 determination. The inhibition rate was calculated as follows:
739
$$\text{Inhibition} = \left(1 - \frac{\text{OD value of sample}}{\text{OD value of negative}}\right) \times 100\%.$$

740

741

742 **Pseudovirus-based neutralization assay.**

743 The SARS-CoV-2 pseudovirus was prepared using the VSV-ΔG
744 system in which the glycoprotein (G) gene was replaced with the firefly
745 luciferase (Fluc) reporter gene^{33,34}. The S protein was overexpressed
746 and displayed on the VSV pseudovirus. Following S-ACE2 interaction,
747 the pseudovirus entered the host cell where the Fluc gene was
748 transcribed and translated. The addition of luciferase substrate
749 resulted in luminescence where the amount of luminescence is
750 proportional to the level of pseudoviral entry. The preparation process
751 of SARS-CoV-2 pseudovirus begins with the cloning of the S gene
752 encoding the S protein of the virus. Subsequently, this gene is inserted
753 into a modified VSV backbone, replacing the original G gene. The
754 resulting construct, containing the S protein gene in lieu of the G gene
755 and complemented by the Fluc reporter gene, forms the foundation of
756 the pseudovirus. The pseudovirus equipped with the S protein can
757 interact with the ACE2 receptor on the surface of host cells, thereby
758 facilitating the entry of the pseudovirus into the cells. Once inside the
759 cells, the Fluc gene will be transcribed and translated to produce
760 luciferase.

761 The assay was conducted following previously described
762 methods^{20,35}. Huh7 cells were seeded at a concentration of 2×10^4

763 cells per well in 96-well plates and incubated until reaching 90-100%
764 confluency, typically around 24 hours. Serum samples, subjected to
765 serial 3-fold dilutions commencing at 1:10, were then incubated with
766 650 TCID₅₀ of the pseudovirus for a precisely controlled duration of 1
767 hour at 37 °C. Dulbecco's modified eagle medium (DMEM) served as
768 the negative control. As a crucial negative control, Dulbecco's Modified
769 Eagle Medium (DMEM) was employed. Following the incubation period,
770 the supernatant was carefully aspirated, making way for the addition of
771 luciferase substrate to each well. A subsequent 2-minute incubation in
772 darkness at room temperature facilitated optimal enzymatic reactions.
773 Luciferase activity, indicative of neutralizing antibody presence, was
774 quantified using the GloMax® 9633 Microplate Luminometer (Promega,
775 Madison, USA).

776

777 **Live virus based neutralization assay.**

778 The assay was conducted as described previously³⁵. To assess the
779 SARS-CoV-2-specific NAb titer in serum, we employed a cytopathic
780 effect (CPE)-based microneutralization assay, utilizing the
781 SARS-CoV-2 virus strain BetaCoV/Beijing/IME-BJ01/2020 (Accession
782 No. GWHACAX01000000) and Vero cells (ATCC, CCL81). Serum
783 samples underwent heat inactivation for 30 minutes at 56 °C and were
784 subsequently two-fold serially diluted (ranging from 1:4 to 1:2048)

785 using Dulbecco's Modified Eagle Medium (DMEM) from Thermo Fisher
786 Scientific. These dilutions were then mixed with an equivalent volume
787 of the virus solution to achieve a 50% tissue culture infectious dose
788 (TCID₅₀) of 100 in each well.

789 The serum-virus mixtures were incubated for 1 hour at 37 °C to
790 allow for sufficient neutralization reactions to occur. Following
791 incubation, the mixtures were gently added to 96-well plates containing
792 semi-confluent Vero cells with a density exceeding 80%. The plates
793 were then incubated for a further 3 days at 37 °C to allow for the
794 development of cytopathic effects (CPEs) on the Vero cells. Using an
795 inverted microscope, the CPEs on the Vero cells were carefully
796 observed and recorded. The neutralizing titer was determined as the
797 reciprocal of the highest sample dilution that successfully protected at
798 least 50% of the cells from CPE. In cases where no neutralization
799 reaction was observable even at the initial serum dilution of 1:4, an
800 arbitrary titer of 2 (half of the limit of quantification) was assigned.

801

802 **Data analysis**

803 To compare the inhibition rate (%) of serum NAbs against the D614G
804 variant and other SARS-CoV-2 variants, the raw inhibition rates of
805 different variants were first normalized using minimum-maximum
806 normalization. Statistical analyses were performed using Student's


807 *t*-test, with a *p*-value ≤ 0.01 considered as statistically significant.

808 Correlations between the SARS-CoV-2 bNAb, ELISA-based serology
809 test, and the cPass sVNT test were determined using Pearson
810 correlation coefficients. Positive and negative percent agreement (PPA,
811 NPA) were performed using the positive and negative judgment results
812 from ELISA-based IgG serology and cPass sVNT tests. Ideal cutoffs
813 for the SARS-CoV-2 bNAb method that maximized PPA and NPA were
814 calculated using the Youden Index, which was implemented in the R
815 package pROC (v 1.18.2)³⁶. All data analyses were carried out in R
816 (v4.2.3) under the R studio (v 19.1.3) environment.


Figure 1

A

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.07.23293304>; this version posted May 10, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



B




C

LOD [µg/mL]	D614G	Alpha	Beta	Delta	Kappa	Omicron BA.1	Average
Luminex	0.19	0.12	0.16	0.23	0.14	0.12	0.16
Wellgrow	0.006	0.003	0.005	0.003	0.007	0.008	0.005
Fold change [L/W] (x)	31.67	40	32	76.67	20	15	35.89±57.80 [-21.91 ~ 93.69]

Figure 2

A

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.07.23293304>; this version posted May 10, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



B




Figure 3





Figure 4

A

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.07.23298934>; this version posted May 10, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



B

	D614G	Alpha	Beta	Delta	Kappa	Omicron BA.1
#26	0.4739	0.511	1.021	0.5504	0.468	3.429
#20	1.365	1.524	1.266	1.343	1.324	> 10
#21	0.8505	0.9199	0.8998	0.8429	0.9445	> 10
#22	> 10	> 10	> 10	> 10	> 10	> 10
#23	> 10	> 10	> 10	> 10	> 10	> 10
#73	> 10	> 10	> 10	> 10	> 10	> 10


IC50 ($\mu\text{g/mL}$)

0 5 10


Figure 5

A

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.07.23293304>; this version posted May 10, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.



B



Vaccine type ◻ Inactivated ◻ Recombinant